A PHASE 1B/2, OPEN-LABEL, MULTICENTRE STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF MEDI4736 IN COMBINATION WITH AZD9150 OR AZD5069 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES AND SUBSEQUENTLY COMPARING AZD9150 AND AZD5069 BOTH AS MONOTHERAPY AND IN COMBINATION WITH MEDI4736 AS SECOND LINE TREATMENT IN PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
- Registry ID
- D5660C00004
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Last update
- 2015-11-18
Conditions
- SQUAMOUS CELL CARCINOMA
- CARCINOMA OF THE HEAD AND NECK
Related clinical trials
- A PHASE 1 FIRST-IN-HUMAN, OPEN-LABEL STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV-711 AS A MONOTHERAPY OR IN COMBINATION WITH BUDIGALIMAB (ABBV-181) IN ADULT SUBJECTS WITH ADVANCED SQUAMOUS TUMORS
- RANDOMIZED PHASE III TRIAL OF NEOADJUVANT IMMUNOTHERAPY WITH RESPONSE ADAPTED TREATMENT VERSUS STANDARD-OF-CARE TREATMENT FOR RESECTABLE STAGE
III/IV CUTANEOUS SQUAMOUS CELL CARCINOMA
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 2/3 STUDY OF FICERAFUSP ALFA
(BCA101) OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST LINE
TREATMENT OF PD-L1-POSITIVE, RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS
CELL CARCINOMA
- A PHASE 2/3, ADAPTIVE, RANDOMIZED, OPEN-LABEL, CLINICAL STUDY TO EVALUATE NEOADJUVANT
AND ADJUVANT V940 (MRNA-4157) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475)
VERSUS STANDARD OF CARE, AND PEMBROLIZUMAB MONOTHERAPY IN PARTICIPANTS WITH
RESECTABLE LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA (LA CSCC)
(INTERPATH-007)
- A RANDOMIZED, PHASE 2, OPEN-LABEL, MULTI-ARM STUDY OF TISLELIZUMAB IN
COMBINATION WITH INVESTIGATIONAL AGENTS AS FIRST-LINE TREATMENT IN PATIENTS
WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
- NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA VERSUS DEFINITIVE CHEMORADIOTHERAPY WITH SALVAGE SURGERY AS NEEDED(NEEDS TRIAL)
View on source registry